ASX - By Stock
|
PYC |
Re:
Ann: New Drug For Major Kidney Disease Effective In Human Models
|
|
Linsanity
|
56 |
18K |
13 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
56
|
18K
|
13
|
|
ASX - By Stock
|
AGN |
Re:
Ann: FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
|
|
Linsanity
|
15 |
4.7K |
5 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
15
|
4.7K
|
5
|
|
ASX - By Stock
|
PYC |
Re:
Ann: New Drug For Major Kidney Disease Effective In Human Models
|
|
Linsanity
|
56 |
18K |
18 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
56
|
18K
|
18
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Wilsons Drug & Device Conference Presentation
|
|
Linsanity
|
2 |
1.6K |
2 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
2
|
1.6K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Linsanity
|
13 |
4.5K |
7 |
25/10/23 |
25/10/23 |
ASX - By Stock
|
13
|
4.5K
|
7
|
|
ASX - By Stock
|
PYC |
Re:
Ann: PYC Presenting on PYC-001 Program at OTS 2023 Meeting
|
|
Linsanity
|
1 |
1.0K |
12 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
1
|
1.0K
|
12
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Investor Presentation ADOA Program
|
|
Linsanity
|
24 |
10K |
8 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
24
|
10K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Investor Presentation ADOA Program
|
|
Linsanity
|
24 |
10K |
2 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
24
|
10K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Investor Presentation ADOA Program
|
|
Linsanity
|
24 |
10K |
9 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
24
|
10K
|
9
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Investor Presentation ADOA Program
|
|
Linsanity
|
24 |
10K |
1 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
24
|
10K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Presentation
|
|
Linsanity
|
16 |
5.9K |
4 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
16
|
5.9K
|
4
|
|
ASX - By Stock
|
PYC |
Re:
Ann: RP11 Clinical Trial Dosing Completed In Patient Cohort 1
|
|
Linsanity
|
42 |
19K |
8 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
42
|
19K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Safety Review Committee Approves Dose Escalation
|
|
Linsanity
|
5 |
1.8K |
1 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
5
|
1.8K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Safety approval VP-001
|
|
Linsanity
|
5 |
2.0K |
4 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
5
|
2.0K
|
4
|
|
ASX - By Stock
|
PYC |
Re:
Price
|
|
Linsanity
|
16 |
5.2K |
0 |
12/09/23 |
12/09/23 |
ASX - By Stock
|
16
|
5.2K
|
0
|
|
ASX - By Stock
|
PYC |
Re:
Price
|
|
Linsanity
|
16 |
5.2K |
1 |
12/09/23 |
12/09/23 |
ASX - By Stock
|
16
|
5.2K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Safety approval VP-001
|
|
Linsanity
|
5 |
2.0K |
0 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
5
|
2.0K
|
0
|
|
ASX - By Stock
|
PYC |
Re:
Ann: RP11 Clinical Trial Dosing Completed In Patient Cohort 1
|
|
Linsanity
|
42 |
19K |
2 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
42
|
19K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
Ann: RP11 Clinical Trial Dosing Completed In Patient Cohort 1
|
|
Linsanity
|
42 |
19K |
2 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
42
|
19K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
IRA act will help orphan drug developers
|
|
Linsanity
|
3 |
1.3K |
8 |
30/08/23 |
30/08/23 |
ASX - By Stock
|
3
|
1.3K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: RP11 Clinical Trial Dosing Completed In Patient Cohort 1
|
|
Linsanity
|
42 |
19K |
5 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
42
|
19K
|
5
|
|
ASX - By Stock
|
PYC |
Re:
Ann: RP11 Clinical Trial Dosing Completed In Patient Cohort 1
|
|
Linsanity
|
42 |
19K |
12 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
42
|
19K
|
12
|
|
ASX - By Stock
|
PYC |
Re:
Ann: PYC Increases Ownership of VP-001 Program
|
|
Linsanity
|
14 |
5.4K |
4 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
14
|
5.4K
|
4
|
|
ASX - By Stock
|
PYC |
Re:
PYC timelines to revenue
|
|
Linsanity
|
11 |
3.3K |
2 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
11
|
3.3K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
New valuation of PYC
|
|
Linsanity
|
27 |
12K |
3 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
27
|
12K
|
3
|
|
ASX - By Stock
|
EYE |
Re:
Ann: i Track Advance Sales in the USA
|
|
Linsanity
|
40 |
8.5K |
4 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
40
|
8.5K
|
4
|
|
ASX - By Stock
|
PYC |
Re:
Ann: PYC Receives FDA Fast Track Designation
|
|
Linsanity
|
11 |
3.8K |
13 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
11
|
3.8K
|
13
|
|
ASX - By Stock
|
PYC |
Re:
Will PYC and NEU be worth $10B in 3 years?
|
|
Linsanity
|
7 |
3.0K |
2 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
7
|
3.0K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Linsanity
|
21 |
6.5K |
4 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
21
|
6.5K
|
4
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Linsanity
|
21 |
6.5K |
1 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
21
|
6.5K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Successful Toxicology Results Pave Way for Phase 2 Trial
|
|
Linsanity
|
6 |
2.7K |
20 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
6
|
2.7K
|
20
|
|
ASX - By Stock
|
PYC |
Re:
PYC turns 2 corners
|
|
Linsanity
|
44 |
18K |
7 |
15/07/23 |
15/07/23 |
ASX - By Stock
|
44
|
18K
|
7
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Advance Notice
|
|
Linsanity
|
22 |
7.8K |
1 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
22
|
7.8K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Advance Notice
|
|
Linsanity
|
22 |
7.8K |
8 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
22
|
7.8K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Advance Notice
|
|
Linsanity
|
22 |
7.8K |
0 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
22
|
7.8K
|
0
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Advance Notice
|
|
Linsanity
|
22 |
7.8K |
7 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
22
|
7.8K
|
7
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Q3 Investor Call Advance Notice
|
|
Linsanity
|
22 |
7.8K |
13 |
11/07/23 |
11/07/23 |
ASX - By Stock
|
22
|
7.8K
|
13
|
|
ASX - By Stock
|
PYC |
Re:
Ann: FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL
|
|
Linsanity
|
14 |
6.4K |
19 |
01/07/23 |
01/07/23 |
ASX - By Stock
|
14
|
6.4K
|
19
|
|
ASX - By Stock
|
PYC |
Re:
Ann: FIRST PATIENT DOSED IN EYE DISEASE CLINICAL TRIAL
|
|
Linsanity
|
14 |
6.4K |
3 |
30/06/23 |
30/06/23 |
ASX - By Stock
|
14
|
6.4K
|
3
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
5 |
16/06/23 |
16/06/23 |
ASX - By Stock
|
29
|
11K
|
5
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
3 |
16/06/23 |
16/06/23 |
ASX - By Stock
|
29
|
11K
|
3
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
0 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
29
|
11K
|
0
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
2 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
29
|
11K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
8 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
29
|
11K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
1 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
29
|
11K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
3 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
29
|
11K
|
3
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
2 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
29
|
11K
|
2
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Phelan-McDermid Syndrome & CNS platform presentation
|
|
Linsanity
|
29 |
11K |
1 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
29
|
11K
|
1
|
|
ASX - By Stock
|
PYC |
Re:
Ann: Central Nervous System Drug Program Added to PYC Pipeline
|
|
Linsanity
|
37 |
17K |
8 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
37
|
17K
|
8
|
|
ASX - By Stock
|
PYC |
Re:
Valuing PYC
|
|
Linsanity
|
89 |
36K |
10 |
05/06/23 |
05/06/23 |
ASX - By Stock
|
89
|
36K
|
10
|
|